Autor segons l'article: Becerra-Tomas, Nerea; Ruiz-Canela, Miguel; Hernandez-Alonso, Pablo; Bullo, Monica; Li, Jun; Guasch-Ferre, Marta; Toledo, Estefania; Clish, Clary B; Estruch, Ramon; Ros, Emilio; Fito, Montserrat; Lee, Chih-Hao; Pierce, Kerry; Aros, Fernando; Serra-Majem, Lluis; Liang, Liming; Razquin, Cristina; Gomez-Gracia, Enrique; Martinez-Gonzalez, Miguel A; Hu, Frank B; Corella, Dolores; Salas-Salvado, Jordi
Departament: Bioquímica i Biotecnologia
e-ISSN: 2218-1989
Autor/s de la URV: Becerra Tomás, Nerea / Bulló Bonet, Mònica / Salas Salvadó, Jorge
Paraules clau: Uric-acid Predimed study Heart failure Glycolysis Glucose Biomarkers Atrial fibrillation
Resum: The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case-control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR (for 1 SD increase): 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies.
Àrees temàtiques: Molecular biology Medicina ii Farmacia Endocrinology, diabetes and metabolism Ciências biológicas ii Ciências biológicas i Biotecnología Biochemistry & molecular biology Biochemistry
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: nerea.becerra@urv.cat monica.bullo@urv.cat jordi.salas@urv.cat
Identificador de l'autor: 0000-0002-4429-6507 0000-0002-0218-7046 0000-0003-2700-7459
Data d'alta del registre: 2024-10-12
Volum de revista: 11
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://www.mdpi.com/2218-1989/11/5/306
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Metabolites. 11 (5): 306-
Referència de l'ítem segons les normes APA: Becerra-Tomas, Nerea; Ruiz-Canela, Miguel; Hernandez-Alonso, Pablo; Bullo, Monica; Li, Jun; Guasch-Ferre, Marta; Toledo, Estefania; Clish, Clary B; Es (2021). Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial. Metabolites, 11(5), 306-. DOI: 10.3390/metabo11050306
DOI de l'article: 10.3390/metabo11050306
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2021
Tipus de publicació: Journal Publications